on ABIVAX (EPA:ABVX)
Abivax: 22 Abstracts on Obefazimod Presented at ECCO 2026
Abivax, a biotechnology company, announced the acceptance of 22 abstracts on obefazimod in inflammatory bowel disease (IBD) at the ECCO 2026 Congress. These presentations include an oral presentation on the antifibrotic properties of the drug.
The data presented cover various aspects, including the efficacy and tolerability of obefazimod, with a focus on ulcerative colitis. Phase 3 ABTECT induction trials revealed a decrease in pro-inflammatory cytokines, indicating early symptom improvement.
Significant findings include potential antifibrotic activity, an innovative approach to treating a serious complication of Crohn's disease for which no effective treatment is currently available.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news